LEP Biomedical

LEP Biomedical have developed a flexible platform technology (HyaGuard™) that effectively delivers anti-inflammatory drugs to the eye following surgeries instead of traditional eye-drops. This simultaneously improves patient quality of life and reduces complications and repeat surgeries.

LEP Biomedical is focused on the glaucoma post-op market due to its long-standing need for such a solution and its market size (>500k procedures performed per year) – 80 million people worldwide with glaucoma. In the US and EU, the cost of glaucoma induced vision loss is $10bn+. LEP Biomedical’s product offers controlled anti-inflammatory release, to reduce post-operative inflammation and scarring in glaucoma patients. HyaGuard™ is a companion product for moderate-refractory drainage surgeries and is positioned as a first mover in post-op care for glaucoma surgeries, with the potential to disrupt the current standard of care and improve patient outcomes.

Key features of HyaGuard™

  • Easily inserted under the conjunctiva (<30 sec)
  • Biodegradable
  • Not externally visible
  • No drops required for the patient
  • Simple and rapid insertion for the surgeon; value add to many surgeries
  • Reduced failures, reoperations and rescues for the healthcare provider

Promoters

  • Dr Alan Hibbitts, CEO/Academic Founder
  • Prof. Colm O’Brien, CMO/Co-Founder

Current status

  • Completed EI Commercialisation Fund
  • Patent filed
  • In vivo proof of concept
  • EI pre-seed start fund investment 2024

Next steps

Seeking seed round of €4.7m which will be used for:

  • Regulatory: RFD/CTA/IND. work
  • Clinical trials: Pre-clinical -> First in human
  • Reimbursement
  • IP filings
  • GMP manufacture
Spin-out summary – LEP Biomedical PDF | 390.6 KB